Work

J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib

Year: 2025

Type: article

Abstract: Aim The J-REGISTER study assessed outcomes and subsequent treatment in patients with EGFR mutation-positive NSCLC treated with first-line afatinib, including patients with uncommon EGFR mutations.Patients & methods This retrospective study assessed 805 patients treated with afatinib in Japan. The primary objective was time on treatment with afatinib. Other objectives included time on treatment from initiation of afatinib until the end of second-line therapy, and overall survival.Results Median time on treatment with afatinib was 13.4 months (14.3/10.1 months in patients with common/uncommon mutations). Median overall time on treatment was highest in patients who received sequential afatinib and osimertinib (32.8 months). Median overall survival was 41.2 months.Conclusion Afatinib is an effective first-line treatment option for Japanese patients with EGFR mutation-positive NSCLC.Clinical trial registration NCT04795245.

Source: Future Oncology

DOI: 10.1080/14796694.2025.2514423

Authors: Teppei Yamaguchi, Haruko Daga, Hisashi Tanaka, Takashi Kijima, Masaya Mizushima

Institutions: Aichi Cancer Center, Osaka City General Hospital, Hirosaki University, Hyogo Medical University, Boehringer Ingelheim (Japan)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: Boehringer Ingelheim